Efficacy Produced from Olverembatinib in Ponatinib-Resistant, T25I-Mutant CML, and Ph-Positive ALLDecember 13th 2022
Those with chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, and those with CML whose tumors have a T315I mutation, were found to have improved efficacy when olverembatinib was given.
Despite Similar Recurrence Scores, Black Patients With HR+ Breast Cancer Have Worse OutcomesDecember 7th 2022
Non-Hispanic Black patients with HR+ breast cancer experienced worse overall outcomes compared with other patient subgroups despite similar recurrence scores, according to a recent analysis of the phase 3 RxPONDER trial.
Updated KEYNOTE-042 Data Show Sustained Survival Benefit at 4 Years in Chinese Patients With Frontline NSCLCApril 10th 2022
Data presented from the 4-year follow-up to the phase 3 KEYNOTE-042 trial display continuous survival benefit of pembrolizumab vs chemotherapy in Chinese patients with untreated non–small cell lung cancer.
Clinical Trial for Patients With Previously Treated Recurrent or Metastatic Cervical Cancer Is Exploring Ociperlimab Plus Tislelizumab ComboMarch 19th 2022
An anti-TIGIT/anti–PD-1 combination approach with ociperlimab plus tislelizumab will be examined in a phase 2 study of patients with previously treated recurrent or metastatic cervical cancer.